Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Expert Opinion / Cases · May 18, 2021

Advanced NSCLC: Anti-PD-1 Rechallenge After Immune-Related Toxicity

Written by
Michael J. Grant MD


Discuss This item Follow

No comments yet, be the first to start the discussion!


    Nov 18, 2021

    subsequent-line chemotherapy +/- anti-VEGF
    autoinmune disease such as rheumatoid arthritis
    anti PDL-1 produce autoinmune toxicity in several location,por example in lung,myocardial,renal,liver amon others

  • May 30, 2024

    Pending Moderator approval.

Further Reading